Cargando…
Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus
Monitoring the levels of IgG antibodies against the SARS-CoV-2 is important during the coronavirus disease 2019 (COVID-19) pandemic, to plan an adequate and evidence-based public health response. After this study we report that the plasma levels of IgG antibodies against SARS-CoV-2 spike protein wer...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9191710/ https://www.ncbi.nlm.nih.gov/pubmed/35696396 http://dx.doi.org/10.1371/journal.pone.0269885 |
_version_ | 1784726075236941824 |
---|---|
author | Papaneophytou, Christos Nicolaou, Andria Pieri, Myrtani Nicolaidou, Vicky Galatou, Eleftheria Sarigiannis, Yiannis Pantelidou, Markella Panayi, Pavlos Thoma, Theklios Stavraki, Antonia Argyrou, Xenia Kalogiannis, Tasos Yiannoukas, Kyriacos Petrou, Christos C. Felekkis, Kyriacos |
author_facet | Papaneophytou, Christos Nicolaou, Andria Pieri, Myrtani Nicolaidou, Vicky Galatou, Eleftheria Sarigiannis, Yiannis Pantelidou, Markella Panayi, Pavlos Thoma, Theklios Stavraki, Antonia Argyrou, Xenia Kalogiannis, Tasos Yiannoukas, Kyriacos Petrou, Christos C. Felekkis, Kyriacos |
author_sort | Papaneophytou, Christos |
collection | PubMed |
description | Monitoring the levels of IgG antibodies against the SARS-CoV-2 is important during the coronavirus disease 2019 (COVID-19) pandemic, to plan an adequate and evidence-based public health response. After this study we report that the plasma levels of IgG antibodies against SARS-CoV-2 spike protein were higher in individuals with evidence of prior infection who received at least one dose of either an mRNA-based vaccine (Comirnaty BNT162b2/Pfizer-BioNTech or Spikevax mRNA-1273/Moderna) or an adenoviral-based vaccine (Vaxzervia ChAdOx1 nCoV-19 /Oxford-Astra Zeneca) (n = 39) compared to i) unvaccinated individuals with evidence of prior infection with SARS-CoV-2 (n = 109) and ii) individuals without evidence of prior infection with SARS-CoV-2 who received one or two doses of one of the aforementioned vaccines (n = 342). Our analysis also revealed that regardless of the vaccine technology (mRNA-based and adenoviral vector-based) two doses achieved high anti- SARS-CoV-2 IgG responses. Our results indicate that vaccine-induced responses lead to higher levels of IgG antibodies compared to those produced following infection with the virus. Additionally, in agreement with previous studies, our results suggest that among individuals previously infected with SARS-CoV-2, even a single dose of a vaccine is adequate to elicit high levels of antibody response. |
format | Online Article Text |
id | pubmed-9191710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-91917102022-06-14 Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus Papaneophytou, Christos Nicolaou, Andria Pieri, Myrtani Nicolaidou, Vicky Galatou, Eleftheria Sarigiannis, Yiannis Pantelidou, Markella Panayi, Pavlos Thoma, Theklios Stavraki, Antonia Argyrou, Xenia Kalogiannis, Tasos Yiannoukas, Kyriacos Petrou, Christos C. Felekkis, Kyriacos PLoS One Research Article Monitoring the levels of IgG antibodies against the SARS-CoV-2 is important during the coronavirus disease 2019 (COVID-19) pandemic, to plan an adequate and evidence-based public health response. After this study we report that the plasma levels of IgG antibodies against SARS-CoV-2 spike protein were higher in individuals with evidence of prior infection who received at least one dose of either an mRNA-based vaccine (Comirnaty BNT162b2/Pfizer-BioNTech or Spikevax mRNA-1273/Moderna) or an adenoviral-based vaccine (Vaxzervia ChAdOx1 nCoV-19 /Oxford-Astra Zeneca) (n = 39) compared to i) unvaccinated individuals with evidence of prior infection with SARS-CoV-2 (n = 109) and ii) individuals without evidence of prior infection with SARS-CoV-2 who received one or two doses of one of the aforementioned vaccines (n = 342). Our analysis also revealed that regardless of the vaccine technology (mRNA-based and adenoviral vector-based) two doses achieved high anti- SARS-CoV-2 IgG responses. Our results indicate that vaccine-induced responses lead to higher levels of IgG antibodies compared to those produced following infection with the virus. Additionally, in agreement with previous studies, our results suggest that among individuals previously infected with SARS-CoV-2, even a single dose of a vaccine is adequate to elicit high levels of antibody response. Public Library of Science 2022-06-13 /pmc/articles/PMC9191710/ /pubmed/35696396 http://dx.doi.org/10.1371/journal.pone.0269885 Text en © 2022 Papaneophytou et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Papaneophytou, Christos Nicolaou, Andria Pieri, Myrtani Nicolaidou, Vicky Galatou, Eleftheria Sarigiannis, Yiannis Pantelidou, Markella Panayi, Pavlos Thoma, Theklios Stavraki, Antonia Argyrou, Xenia Kalogiannis, Tasos Yiannoukas, Kyriacos Petrou, Christos C. Felekkis, Kyriacos Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus |
title | Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus |
title_full | Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus |
title_fullStr | Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus |
title_full_unstemmed | Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus |
title_short | Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus |
title_sort | seroprevalence of immunoglobulin g antibodies against sars-cov-2 in cyprus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9191710/ https://www.ncbi.nlm.nih.gov/pubmed/35696396 http://dx.doi.org/10.1371/journal.pone.0269885 |
work_keys_str_mv | AT papaneophytouchristos seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT nicolaouandria seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT pierimyrtani seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT nicolaidouvicky seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT galatoueleftheria seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT sarigiannisyiannis seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT pantelidoumarkella seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT panayipavlos seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT thomatheklios seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT stavrakiantonia seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT argyrouxenia seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT kalogiannistasos seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT yiannoukaskyriacos seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT petrouchristosc seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus AT felekkiskyriacos seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus |